Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

Blood Cancer Journal

Volumn 5, Issue 5, 2015, Pages

  Hideshima, T ^a   Cottini, F ^a   Ohguchi, H ^a   Jakubikova, J ^a   Gorgun, G ^a   Mimura, N ^a   Tai, Y T ^a   Munshi, N C ^a   Richardson, P G ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CEREBLON; DEXAMETHASONE; ENTINOSTAT; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; MYC PROTEIN; ONCOPROTEIN; PANOBINOSTAT; POMALIDOMIDE; RICOLINOSTAT; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; SMALL INTERFERING RNA; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; DRUG POTENTIATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOMODULATION; IN VITRO STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; IMMUNOMODULATION; IN VITRO TECHNIQUES; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; THALIDOMIDE; TRANSFECTION;

EID: 84989285802     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.38     Document Type: Article

References (41)

1. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
2. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
3. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
4. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301-305.
5. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014; 343: 305-309.
6. Kuehl WM, Brents LA, Chesi M, Huppi K, Bergsagel PL. Dysregulation of c-myc in multiple myeloma. Curr Top Microbiol Immunol 1997; 224: 277-282.
7. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood 2012; 120: 2450-2453.
8. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor- 4, providing a potential mechanistic link for predicting response. Br J Haematol 2011; 154: 325-336.
9. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238-243.
10. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673-691.
11. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003; 102: 2615-2622.
12. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540-545.
13. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
14. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study. Lancet Oncol 2013; 14: 1129-1140.
15. Hideshima H, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567-8572.
16. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-2589.
17. Hideshima T, Mazitschek R, Santo L, Mimura N, Gorgun G, Richardson PG et al. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 2014; 28: 457-460.
18. Yee AJ, Voorhees PM, Bensinger W, Berdeja JG, Supko JG, Richardson PG et al. Ricolinostat (ACY-1215), a selective HDAC6 inhibitor, in combination with lenalidomide and dexamethasone: Results of a phase 1b trial in relapsed and relapsed refractory multiple myeloma. American Society of Hematlogy Annual Meeting. Blood 2014; 124: Abstract number 4772.
19. Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2014; 28: 580-690.
20. Li H, Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 2004; 324: 860-867.
21. Xu Y, Voelter-Mahlknecht S, Mahlknecht U. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Int J Mol Med 2005; 15: 169-172.
22. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003; 101: 2377-2380.
23. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
24. Thompson EB. The many roles of c-Myc in apoptosis. Annual Rev Physiol 1998; 60: 575-600.
25. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
26. Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: Basic and clinical updates. Int J Hematol 2013; 97: 313-323.
27. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1-11.
28. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
29. Moros A, Rodriguez V, Saborit-Villarroya I, Montraveta A, Balsas P, Sandy P et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia 2014; 28: 2049-2059.
30. Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 2007; 31: 1403-1411.
31. Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barille-Nion S. Impact of XIAP protein levels on the survival of myeloma cells. Haematologica 2009; 94: 87-93.
32. Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernandez-Lazaro D et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010; 95: 794-803.
33. Vogl DT, Raje N, Hari P, Jones SS, Supko JG, Leone G et al. Phase 1B results of ricolinostat (ACY-1215) combination therapy with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (MM). American Society of Hematology Annual Meeting. Blood 2014; 124: Abstract number 4764.
34. Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 2014; 124: 536-545.
35. Chrousos GP, Kino T. Ikaros transcription factors: Flying between stress and inflammation. J Clin Invest 2005; 115: 844-848.
36. Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K et al. Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: Therapeutic implications. Blood 2009; 113: 5228-5236.
37. Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood 2010; 115: 3772-3775.
38. Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014; 123: 1461-1469.
39. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679-686.
40. Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014; 28: 690-693.
41. Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-hodgkin lymphoma cells. Mol Cancer Ther 2014; 13: 2886-2897.